Navigation Links
U.S. Expects 160 Million Doses of Swine Flu Vaccine by October
Date:7/23/2009

A slowdown in production is hampering efforts, but a nasal spray version might help

THURSDAY, July 23 (HealthDay News) -- 160 million: that's the number of doses of injectable swine flu vaccine U.S. officials now expect to have on hand by October, with more doses coming in the form of a nasal spray.

Since immunization is expected to depend on each person getting two doses spread a month apart, the amount of vaccine will still only cover a fraction of the population, but more is expected to arrive in the following months, the Associated Press reported Thursday.

Earlier in the day, the U.S. Food and Drug Administration convened a meeting with the world's five leading flu vaccine makers to assess how many doses might be available. Jerry Weir, an FDA official charged with overseeing vaccine production, told the AP that the H1N1 swine flu vaccine is proving more difficult to grow in the standard way (using chicken eggs) than typical seasonal flu vaccines. In fact, the yield is just 30 percent of normal.

The Department of Health and Human Services is responsible for buying up and distributing new vaccine stocks. Robin Robinson, who helps direct the HHS effort, told the AP that his team is keeping the production slowdown in mind as HHS buys and distributes new vaccine stocks.

But there was brighter news, as well. Maryland-based Medimmune Inc. told U.S. officials on Thursday that it expects to have 14 million doses of a swine flu version of its FluMist nasal spray vaccine ready to distribute across the U.S. by October, and would have even more available if it could get the vaccine into its spray devices fast enough. Tens of millions more doses will be ready to be bottled, the company said, and it's possible that a sprayer may not even be necessary - it may be enough to administer droplets of the vaccine into the nose.

"A dropper instead of a sprayer works well," MedImmune vice-president Dr. Ben Machielse told the AP. Medimmune said it plans to begin trials in August to make sure the H1N1 version of the nasal vaccine has no more side effects than the vaccine for the seasonal flu.

Also on Thursday, experts at the U.S. Centers for Disease Control and Prevention said that the virus has not yet mutated to become more dangerous, although they continue to follow its progress globally, the AP reported. Dr. Nancy Cox, chief of CDC's influenza division, called the lack of genetic variation in the H1N1 strain "quite surprising" given the pathogen's quick spread.

In the meantime, the United States is readying its first human trials of an experimental vaccine to protect against the H1N1 swine flu virus, officials announced Wednesday.

Two possible vaccines will be tested at eight institutions around the country under the auspices of the National Institute of Allergy and Infectious Diseases (NIAID), officials said.

The purpose of the trials, said NIAID Director Dr. Anthony S. Fauci in a prepared statement, is to "determine whether the vaccines are safe and to assess their ability to induce protective immune responses. These data will be factored into the decision about how and if to implement a 2009 H1N1 flu immunization program this fall."

The announcement followed Tuesday's revelation that two Australian biotechnology companies have started inoculating adult volunteers in the world's first H1N1 swine flu vaccine trials. Those trials, as well as the trials planned in the United States, hope to produce an effective shot against the virus that has so far killed more than 700 people worldwide.

In the United States, several trials will be conducted concurrently, officials said.

"I think the speed with which they [federal officials] got this going is impressive," said one expert, Dr. John J. Treanor, professor of medicine and of microbiology and immunology at the University of Rochester Medical Center, in New York. "They have a really well-organized clinical trials infrastructure that is uniquely posed to do these kinds of studies when there's an emergency situation like there is now."

One of the NIAID studies will try to determine if one or two 15-microgram doses of the candidate H1N1 vaccine are sufficient to provoke an immune response in healthy adults aged 18 to 64 and in people aged 65 and older. Studies will also look at whether one or two doses of 30 micrograms are more effective.

The two-dose regimens will be given three weeks apart. Two manufacturers, Sanofi Pasteur and CSL Biotherapies, produced the vaccines.

If these trials seem safe, the vaccines will also be tested in children aged 6 months to 17 years, according to the NIAID statement.

"The response to the vaccine may vary in different age groups," said Dr. Karen Kotloff, a professor of pediatrics and lead investigator at the Vaccine and Treatment Evaluation Unit at the University of Maryland, one of the medical centers chosen for the trials. In a statement released by the university, Kotloff explained that age could make a difference in vaccine response because "young people have not seen a flu virus like this before," whereas older Americans might have been exposed to H1N1 type strains in the past.

Additional trials will look at concurrent administration of the swine flu vaccine with regular, seasonal vaccine.

"It makes sense to test the combined swine flu and seasonal flu vaccines because there are some populations in whom both vaccines are indicated," Treanor said. "It would certainly be easier to give them at the same time but these trials are mostly focused on making sure they don't interfere with each other in some way and that they still get a good response."

Besides the University of Maryland School of Medicine, other centers taking part in the trials include the University of Iowa; St. Louis University; Baylor College of Medicine in Houston; Children's Hospital Medical Center, Cincinnati; Emory University in Atlanta; Group Health Cooperative, Seattle; and Vanderbilt University in Nashville, officials said.

In Australia, Adelaide-based drug manufacturer Vaxine initiated trials Monday with 300 participants, while Melbourne's CSL has 240 people in its seven-month study. Australia had 14,703 confirmed cases of swine flu as of Wednesday, and at least 41 deaths, according to the AP. The winter flu season is well under way in the Southern Hemisphere.

Both companies said it would be at least six weeks before results of the initial trials are known.

Right now, flu season is peaking in the Southern Hemisphere. As was the case when the H1N1 swine flu virus first surfaced in Mexico and then the United States in mid-April, infections in the Southern Hemisphere continue to be relatively mild, much like the seasonal flu, and recovery is fairly quick.

As vaccine development continues, the H1N1 swine flu virus continues to sweep around the world.

The CDC was reporting last Friday -- the most recent numbers available -- 40,617 confirmed cases of H1N1 infection and 263 deaths in the United States, although officials believe that more than 1 million Americans have been stricken with the swine flu. The reason for the disparity: The virus continues to produce mild symptoms and patients typically recover quickly.

Officials expect to see a new outbreak of H1N1 swine flu in the United States in the fall. It will most likely start earlier than seasonal flu, Dr. Anne Schuchat, director of the CDC's National Center for Immunization and Respiratory Diseases, said during a Friday press conference. Seasonal flu typically surfaces in late fall.

Unlike seasonal flu, the H1N1 flu continues to pose more problems for younger people, Schuchat added. "There are higher attack rates and hospitalizations in younger adults and children," she said.

U.S. Human Cases of H1N1 Flu Infection
(As of July 17, 2009, 11 AM ET)
States and Territories* # of
confirmed and
probable cases
Deaths
Alabama
477
 
Alaska
218
 
Arizona
762
11
Arkansas
47
 
California
3161
52
Colorado
155
 
Connecticut
1581
7
Delaware
364
 
Florida
2188
12
Georgia
174
1
Hawaii
722
1
Idaho
143
 
Illinois
3357
15
Indiana
282
1
Iowa
165
 
Kansas
186
 
Kentucky
143
 
Louisiana
232
 
Maine
133
 
Maryland
732
3
Massachusetts
1343
5
Michigan
515
8
Minnesota
660
3
Mississippi
219
 
Missouri
70
1
Montana
94
 
Nebraska
264
1
Nevada
406
 
New Hampshire
247
 
New Jersey
1350
14
New Mexico
232
 
New York
2670
57
North Carolina
395
4
North Dakota
61
 
Ohio
161
1
Oklahoma
176
1
Oregon
465
5
Pennsylvania
1914
8
Rhode Island
188
2
South Carolina
244
 
South Dakota
39
 
Tennessee
247
1
Texas
4975
24
Utah
966
14
Vermont
59
 
Virginia
319
2
Washington
636
4
Washington, D.C.
45
 
West Virginia
227
 
Wisconsin
6031
5
Wyoming
106
 
Territories
American Samoa
8
 
Guam
1
 
Puerto Rico
18
 
Virgin Islands
44
 
TOTAL (55)*
40,617 cases
263 deaths
*includes the District of Columbia, American Samoa, Guam,
Puerto Rico and the Virgin Islands

Source: U.S. Centers for Disease Control and Prevention

More information

There's more on the flu at the U.S. Department of Health and Human Services.



SOURCES: John J. Treanor M.D., professor, medicine, microbiology and immunology, University of Rochester Medical Center, Rochester, N.Y.; July 22, 2009, news releases, U.S. National Institute of Allergy and Infectious Diseases, and University of Maryland School of Medicine; July 17, 2009, teleconference with Anne Schuchat, M.D., director, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention; Associated Press


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved


Related medicine news :

1. Market Scope Expects Retina Pharmaceutical Industry to Top $3.5 Billion by 2014
2. Hillenbrand Expects to Report Second-Quarter Net Revenue of $170.8 Million and Revises 2009 Guidance
3. HealthGrades Expects Third Quarter Revenue of Approximately $10 Million : Full-Year 2008 Ratings and Advisory Revenue to Be $39 Million to $40 Million Company Provides Update on Stock Repurchase Program
4. ATS Medical Expects Second Quarter Revenue of $16.7 to $16.9 Million
5. Chubb Expects to Release Earnings on July 24 and Hold Conference Call on the Same Day
6. NightHawk Radiology Holdings, Inc. Announces Preliminary Results of Its Tender Offer; NightHawk Expects to Purchase 2,367,438 Shares of Its Common Stock at $8.05 per Share
7. ATS Medical Expects Fourth Quarter Revenue to Increase by Approximately 32%
8. ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device; Expects Sales to Increase 30%
9. Jury Awards Valley Medical Center Patient $1.8 Million for Nursing Negligence
10. National Stroke Quality Improvement Program Passes the Million Mark
11. 10 Million Workers Gain New Health and Behavior Change Tool - eMindful Courses Offered to Client of Leading Online Health Change Provider
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that ... Bank of Eastern Michigan last Friday in order to aid in the Flint water ... to include a facility located in Clio, only 15 miles away from Flint. , ...
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... Middletown, PA (PRWEB) , ... February 10, 2016 , ... ... to offer two webinars in February 2016. Each webinar features a dynamic expert ... therapy to benefit their athletes, patients and facilities. Both events are free to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced ... Emergency Medicine , an emergency medicine professional association, to support the organization's newly ... The American Academy of Emergency Medicine, or AAEM, seeks to empower emergency physicians ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... of a master charity program created to assist the local community. Pledging to ... community leaders and nonprofit organizations in the area. Their goal is to bring ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... DIEGO , Feb. 11, 2016 ... groundbreaking cell-isolation method that opens the door to ... until now have been impossible to isolate with ... to isolate specific tumor types in various stages ... genetic variants of these cells that are clinically ...
(Date:2/11/2016)... Conn. , Feb. 11, 2016  NanoViricides, ... that it has entered into an agreement with ... its nanoviricides® drug candidates in standard animal models ... Romanowski , Research Director. Dr. Romanowski has extensive ... discovery. --> Eric Romanowski , ...
(Date:2/11/2016)... -- North America , Europe ... global market is expected to reach USD 20,190.1 Million by 2020 ... 10.2%. --> North America , ... The global market is expected to reach USD 20,190.1 Million by ... of 10.2%. --> According to a new market research ...
Breaking Medicine Technology: